8月18日，福泰制药盘中上涨3.09%，报531.475美元/股，成交额2.2亿美元。
消息面上，RBC Capital近期发布研报指出，福泰制药拥有多个潜在管线催化剂，整体风险收益比偏正面。具体包括：下半年将公布VX-828囊性纤维化一期临床数据，积极结果有望巩固其竞争优势；IgA肾病药物povetacicept的FDA审批日期为11月30日，基于强劲的三期中期数据，获批概率较高。此外，此前竞争对手药物研发未达预期，进一步强化了公司在囊性纤维化领域的领先地位。公司二季度营收33.34亿美元超预期，全年收入指引上调至131亿至132亿美元，多家机构维持买入评级，目标价普遍高于当前股价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.